RNA interference in the clinic: challenges and future directions

Inherent difficulties with blocking many desirable targets using conventional approaches have prompted many to consider using RNA interference (RNAi) as a therapeutic approach. Although exploitation of RNAi has immense potential as a cancer therapeutic, many physiological obstacles stand in the way of successful and efficient delivery. This Review explores current challenges to the development of synthetic RNAi-based therapies and considers new approaches to circumvent biological barriers, to avoid intolerable side effects and to achieve controlled and sustained release.

[1]  J. M. Thomson,et al.  Argonaute2 Is the Catalytic Engine of Mammalian RNAi , 2004, Science.

[2]  T. Tuschl,et al.  Mechanisms of gene silencing by double-stranded RNA , 2004, Nature.

[3]  Anil K Sood,et al.  Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. , 2005, Cancer research.

[4]  T. Tuschl,et al.  Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs. , 2004, Molecular cell.

[5]  Y. Omidi,et al.  Toxicogenomics of cationic lipid-based vectors for gene therapy: impact of microarray technology. , 2005, Current drug delivery.

[6]  Marion Jurk,et al.  Identification of RNA Sequence Motifs Stimulating Sequence-Specific TLR8-Dependent Immune Responses1 , 2008, The Journal of Immunology.

[7]  F. He,et al.  Cationic lipids enhance siRNA-mediated interferon response in mice. , 2005, Biochemical and biophysical research communications.

[8]  D. Haber,et al.  Coexpression of Argonaute-2 enhances RNA interference toward perfect match binding sites , 2008, Proceedings of the National Academy of Sciences.

[9]  M. Stoffel,et al.  Mechanisms and optimization of in vivo delivery of lipophilic siRNAs , 2007, Nature Biotechnology.

[10]  Martin L. Miller,et al.  Transfection of small RNAs globally perturbs gene regulation by endogenous microRNAs , 2009, Nature Biotechnology.

[11]  Hiroshi Maeda,et al.  Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. , 2010, Bioconjugate chemistry.

[12]  David Cameron,et al.  2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial , 2007, The Lancet.

[13]  V. Kim,et al.  Regulating the Regulators: Posttranslational Modifications of RNA Silencing Factors , 2009, Cell.

[14]  Jan-Fang Cheng,et al.  Dicer, Drosha, and outcomes in patients with ovarian cancer. , 2008, The New England journal of medicine.

[15]  Mauro Ferrari,et al.  Mathematical modeling of cancer progression and response to chemotherapy , 2006, Expert review of anticancer therapy.

[16]  A. Judge,et al.  Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA , 2005, Nature Biotechnology.

[17]  S. Skinner,et al.  Microvascular architecture of experimental colon tumors in the rat. , 1990, Cancer research.

[18]  Mauro Ferrari,et al.  Design maps for nanoparticles targeting the diseased microvasculature. , 2008, Biomaterials.

[19]  Jeong Won Lee,et al.  Targeted Gene Silencing Using RGD-Labeled Chitosan Nanoparticles , 2010, Clinical Cancer Research.

[20]  R. Vandenbroucke,et al.  Maintaining the silence: reflections on long-term RNAi , 2008, Drug Discovery Today.

[21]  Suzie H Pun,et al.  Extracellular barriers to in Vivo PEI and PEGylated PEI polyplex-mediated gene delivery to the liver. , 2008, Bioconjugate chemistry.

[22]  L. Perlemuter [From theory to practice]. , 1997, Soins. Psychiatrie.

[23]  M Ferrari,et al.  The receptor-mediated endocytosis of nonspherical particles. , 2008, Biophysical journal.

[24]  J. Geddes,et al.  What is a randomised controlled trial? , 2009, Epidemiologia e Psichiatria Sociale.

[25]  Mauro Ferrari,et al.  Enabling individualized therapy through nanotechnology. , 2010, Pharmacological research.

[26]  Domenico Catalano,et al.  MitoDrome: a database of Drosophila melanogaster nuclear genes encoding proteins targeted to the mitochondrion , 2003, Nucleic Acids Res..

[27]  F. Liu,et al.  “New”‐clear functions of PDK1: Beyond a master kinase? , 2005, Journal of cellular biochemistry.

[28]  Dipali G. Sashital,et al.  Structural insights into RNA interference. , 2010, Current opinion in structural biology.

[29]  P. Linsley,et al.  Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application , 2010, Nature Reviews Drug Discovery.

[30]  R. Duncan The dawning era of polymer therapeutics , 2003, Nature Reviews Drug Discovery.

[31]  Eva Harth,et al.  Targeted nanoparticles that deliver a sustained, specific release of Paclitaxel to irradiated tumors. , 2010, Cancer research.

[32]  John J. Rossi,et al.  Strategies for silencing human disease using RNA interference , 2007, Nature Reviews Genetics.

[33]  Mauro Ferrari,et al.  Sustained small interfering RNA delivery by mesoporous silicon particles. , 2010, Cancer research.

[34]  C. Echeverri,et al.  RNAi and iTRAQ reagents united: targeted quantitation of siRNA-mediated protein silencing in human cells , 2009, Analytical and bioanalytical chemistry.

[35]  A. Zychlinsky,et al.  Neutrophil Extracellular Traps Kill Bacteria , 2004, Science.

[36]  S M Moghimi,et al.  Long-circulating and target-specific nanoparticles: theory to practice. , 2001, Pharmacological reviews.

[37]  Helmut Friess,et al.  Pancreatic cancer microenvironment , 2007, International journal of cancer.

[38]  Mark E. Davis,et al.  Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging , 2006, Nucleic acids research.

[39]  H. Maeda,et al.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.

[40]  M. Ferrari,et al.  The Effective Dispersion of Nanovectors Within the Tumor Microvasculature , 2006, Annals of Biomedical Engineering.

[41]  R. Bast,et al.  SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer. , 2010, Cancer cell.

[42]  G. Calin,et al.  Regulation of tumor angiogenesis by EZH2. , 2010, Cancer cell.

[43]  V. Kim MicroRNA biogenesis: coordinated cropping and dicing , 2005, Nature Reviews Molecular Cell Biology.

[44]  Qi Zhou,et al.  Chemically Modified Short Interfering Hybrids (siHYBRIDS): Nanoimmunoliposome Delivery In Vitro and In Vivo for RNAi of HER-2 , 2006, Nucleosides, nucleotides & nucleic acids.

[45]  P. Kesharwani,et al.  Dendrimer toxicity: Let's meet the challenge. , 2010, International journal of pharmaceutics.

[46]  T. Rana,et al.  Illuminating the silence: understanding the structure and function of small RNAs , 2007, Nature Reviews Molecular Cell Biology.

[47]  T. Park,et al.  Local and systemic delivery of VEGF siRNA using polyelectrolyte complex micelles for effective treatment of cancer. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[48]  Mauro Ferrari,et al.  Frontiers in cancer nanomedicine: directing mass transport through biological barriers. , 2010, Trends in biotechnology.

[49]  L. Kwak,et al.  Detection of tumor messenger RNA in the serum of patients with malignant melanoma. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[50]  P. Zamore,et al.  Kinetic analysis of the RNAi enzyme complex , 2004, Nature Structural &Molecular Biology.

[51]  Matthias John,et al.  Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs , 2004, Nature.

[52]  Henning Urlaub,et al.  Single-Stranded Antisense siRNAs Guide Target RNA Cleavage in RNAi , 2002, Cell.

[53]  Theresa A. Storm,et al.  Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways , 2006, Nature.

[54]  R. Langer,et al.  Lipid‐based nanotherapeutics for siRNA delivery , 2010, Journal of internal medicine.

[55]  Francisco Cervantes,et al.  Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. , 2006, The New England journal of medicine.

[56]  S. Lim,et al.  FERM control of FAK function: Implications for cancer therapy , 2008, Cell cycle.

[57]  Yin Zhang,et al.  In Vivo Imaging of RNA Interference , 2010, Journal of Nuclear Medicine.

[58]  A. Tari,et al.  Cellular Pharmacology of P-ethoxy Antisense Oligonucleotides Targeted to Bcl-2 in a Follicular Lymphoma Cell Line , 2003, Leukemia & lymphoma.

[59]  A. Judge,et al.  siRNA and innate immunity. , 2009, Oligonucleotides.

[60]  Joshua T. Burdick,et al.  Common genetic variants account for differences in gene expression among ethnic groups , 2007, Nature Genetics.

[61]  Shan Jiang,et al.  Quantum-dot based nanoparticles for targeted silencing of HER2/neu gene via RNA interference. , 2007, Biomaterials.

[62]  Shizuo Akira,et al.  The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses , 2004, Nature Immunology.

[63]  Hyunsoo Kim,et al.  Single-nucleotide polymorphisms inside microRNA target sites influence tumor susceptibility. , 2010, Cancer research.

[64]  P. Thall,et al.  Dose‐Finding Based on Efficacy–Toxicity Trade‐Offs , 2004, Biometrics.

[65]  Justine R. Smith,et al.  Sequence- and target-independent angiogenesis suppression by siRNA via TLR3 , 2008, Nature.

[66]  D. Balding,et al.  HLA Sequence Polymorphism and the Origin of Humans , 2006 .

[67]  A. Fire,et al.  Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans , 1998, Nature.

[68]  Vishnu Swarup,et al.  Circulating (cell‐free) nucleic acids – A promising, non‐invasive tool for early detection of several human diseases , 2007, FEBS letters.

[69]  T. Ochiya,et al.  Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[70]  A. J. Tavares,et al.  Quantum dots as contrast agents for in vivo tumor imaging: progress and issues , 2011, Analytical and bioanalytical chemistry.

[71]  T. Park,et al.  Comparative evaluation of target-specific GFP gene silencing efficiencies for antisense ODN, synthetic siRNA, and siRNA plasmid complexed with PEI-PEG-FOL conjugate. , 2006, Bioconjugate chemistry.

[72]  A. Klippel,et al.  Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. , 2003, Nucleic acids research.

[73]  K. Czaplinski,et al.  Exportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs. , 2004, RNA.

[74]  P. Opolon,et al.  Intravenous delivery of anti-RhoA small interfering RNA loaded in nanoparticles of chitosan in mice: safety and efficacy in xenografted aggressive breast cancer. , 2006, Human gene therapy.

[75]  Parag Aggarwal,et al.  Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. , 2008, Molecular pharmaceutics.

[76]  K. Baggerly,et al.  Dual targeting of EphA2 and FAK in ovarian carcinoma , 2009, Cancer biology & therapy.

[77]  G. Hannon,et al.  Unlocking the potential of the human genome with RNA interference , 2004, Nature.

[78]  M. Hung,et al.  Survival of cancer cells is maintained by EGFR independent of its kinase activity. , 2008, Cancer cell.

[79]  D. Dykxhoorn,et al.  Breaking down the barriers: siRNA delivery and endosome escape , 2010, Journal of Cell Science.

[80]  L. Lim,et al.  Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing. , 2006, RNA.

[81]  Rakesh K. Jain,et al.  Vascular Normalization by Vascular Endothelial Growth Factor Receptor 2 Blockade Induces a Pressure Gradient Across the Vasculature and Improves Drug Penetration in Tumors , 2004, Cancer Research.

[82]  Jürgen Groll,et al.  Phagocytosis independent extracellular nanoparticle clearance by human immune cells. , 2010, Nano letters.

[83]  S. Grinstein,et al.  The Tangled Webs That Neutrophils Weave , 2004, Science.

[84]  Anne Gatignol,et al.  Combinatorial delivery of small interfering RNAs reduces RNAi efficacy by selective incorporation into RISC , 2007, Nucleic acids research.

[85]  A. Sood,et al.  The dicey role of Dicer: implications for RNAi therapy. , 2010, Cancer research.

[86]  S. Aaronson,et al.  Implications for Cancer Therapy , 2003 .

[87]  Eric Pridgen,et al.  Factors Affecting the Clearance and Biodistribution of Polymeric Nanoparticles , 2008, Molecular pharmaceutics.

[88]  Robert Langer,et al.  A combinatorial library of lipid-like materials for delivery of RNAi therapeutics , 2008, Nature Biotechnology.

[89]  T. Rana,et al.  Translation Repression in Human Cells by MicroRNA-Induced Gene Silencing Requires RCK/p54 , 2006, PLoS biology.

[90]  Y. Rojanasakul,et al.  Oxygen Radical-Mediated Pulmonary Toxicity Induced by Some Cationic Liposomes , 2000, Pharmaceutical Research.

[91]  Mark E. Davis,et al.  Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA , 2007, Proceedings of the National Academy of Sciences.

[92]  Kathryn A. Whitehead,et al.  Lipid-like materials for low-dose, in vivo gene silencing , 2010, Proceedings of the National Academy of Sciences.

[93]  C. Burge,et al.  The Widespread Impact of Mammalian MicroRNAs on mRNA Repression and Evolution , 2005, Science.

[94]  Mark E. Davis,et al.  Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles , 2010, Nature.

[95]  Mauro Ferrari,et al.  The mathematical engines of nanomedicine. , 2008, Small.

[96]  S. Pun,et al.  3-D tissue culture systems for the evaluation and optimization of nanoparticle-based drug carriers. , 2008, Bioconjugate chemistry.

[97]  L. Lim,et al.  Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity. , 2006, RNA.

[98]  H. Bonnefoi,et al.  Telomerase RNA as a detection marker in the serum of breast cancer patients. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[99]  B. Li,et al.  Expression profiling reveals off-target gene regulation by RNAi , 2003, Nature Biotechnology.

[100]  M. Estévez,et al.  Nanoparticle-aptamer conjugates for cancer cell targeting and detection. , 2010, Methods in molecular biology.

[101]  A. C. Hunter Molecular hurdles in polyfectin design and mechanistic background to polycation induced cytotoxicity. , 2006, Advanced drug delivery reviews.

[102]  H. Kawachi,et al.  Chemically modified siRNA prolonged RNA interference in renal disease. , 2007, Biochemical and biophysical research communications.

[103]  M. Manoharan,et al.  RNAi therapeutics: a potential new class of pharmaceutical drugs , 2006, Nature chemical biology.